TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Alnylam Pharmaceuticals Announces Interim Phase 1 Data of Nucresiran
Express News | Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
